The role of postmastectomy radiotherapy in clinically nodepositive, stage II-III breast cancer patients with pathological negative nodes after neoadjuvant chemotherapy: An analysis from the NCDB

Oncotarget

Volumn 7, Issue 17, 2016, Pages 24848-24859

  Liu, Jieqiong ^a,b   Mao, Kai ^a,b   Jiang, Shuai ^c   Jiang, Wen ^d   Chen, Kai ^a,b   Kim, Betty Y S ^e   Liu, Qiang ^a   Jacobs, Lisa K ^b  

^a SUN YAT SEN UNIVERSITY   (China)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^d UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^e MAYO CLINIC   (United States)

Author keywords

Breast cancer; Complete pathological nodal response; Neoadjuvant chemotherapy; Postmastectomy radiotherapy; Survival benefit

Indexed keywords

ANTINEOPLASTIC AGENT;

ADULT; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; DRUG EFFECT; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MASTECTOMY; MIDDLE AGED; OVERALL SURVIVAL; SURVIVAL TIME; TREATMENT OUTCOME; TREATMENT PLANNING; ADJUVANT RADIOTHERAPY; AGED; BREAST TUMOR; MORTALITY; NEOADJUVANT THERAPY; PATHOLOGY; POSTOPERATIVE CARE; PROCEDURES; SURVIVAL ANALYSIS; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; FEMALE; HUMANS; MASTECTOMY; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM STAGING; POSTOPERATIVE CARE; RADIOTHERAPY, ADJUVANT; SURVIVAL ANALYSIS; YOUNG ADULT;

EID: 84966671397     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.6664     Document Type: Article

References (24)

1. Kyndi M, Sorensen FB, Knudsen H, Overgaard M, Nielsen HM and Overgaard J. Estrogen receptor, progesterone receptor, HER-2, and response to postmastectomy radiotherapy in high-risk breast cancer: the Danish Breast Cancer Cooperative Group. J Clin Oncol. 2008; 26:1419-1426.
2. Goldhirsch A, Ingle JN, Gelber RD, Coates AS, Thurlimann B and Senn HJ. Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009. Ann Oncol. 2009; 20:1319-1329.
3. Recht A, Edge SB, Solin LJ, Robinson DS, Estabrook A, Fine RE, Fleming GF, Formenti S, Hudis C, Kirshner JJ, Krause DA, Kuske RR, Langer AS, et al. Postmastectomy radiotherapy: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol. 2001; 19:1539-1569.
4. Huang EH, Tucker SL, Strom EA, McNeese MD, Kuerer HM, Buzdar AU, Valero V, Perkins GH, Schechter NR, Hunt KK, Sahin AA, Hortobagyi GN and Buchholz TA. Postmastectomy radiation improves local-regional control and survival for selected patients with locally advanced breast cancer treated with neoadjuvant chemotherapy and mastectomy. J Clin Oncol. 2004; 22:4691-4699.
5. Buchholz TA, Tucker SL, Masullo L, Kuerer HM, Erwin J, Salas J, Frye D, Strom EA, McNeese MD, Perkins G, Katz A, Singletary SE, Hunt KK, Buzdar AU and Hortobagyi GN. Predictors of local-regional recurrence after neoadjuvant chemotherapy and mastectomy without radiation. J Clin Oncol. 2002; 20:17-23.
6. Wright JL, Takita C, Reis IM, Zhao W, Saigal K, Wolfson A, Markoe A, Moller M and Hurley J. Predictors of locoregional outcome in patients receiving neoadjuvant therapy and postmastectomy radiation. Cancer. 2013; 119:16-25.
7. Buchholz TA, Lehman CD, Harris JR, Pockaj BA, Khouri N, Hylton NF, Miller MJ, Whelan T, Pierce LJ, Esserman LJ, Newman LA, Smith BL, Bear HD and Mamounas EP. Statement of the science concerning locoregional treatments after preoperative chemotherapy for breast cancer: a National Cancer Institute conference. J Clin Oncol. 2008; 26:791-797.
8. Le Scodan R, Selz J, Stevens D, Bollet MA, de la Lande B, Daveau C, Lerebours F, Labib A and Bruant S. Radiotherapy for stage II and stage III breast cancer patients with negative lymph nodes after preoperative chemotherapy and mastectomy. Int J Radiat Oncol Biol Phys. 2012; 82:e1-7.
9. Fowble BL, Einck JP, Kim DN, McCloskey S, Mayadev J, Yashar C, Chen SL and Hwang ES. Role of postmastectomy radiation after neoadjuvant chemotherapy in stage II-III breast cancer. Int J Radiat Oncol Biol Phys. 2012; 83:494-503.
10. Shim SJ, Park W, Huh SJ, Choi DH, Shin KH, Lee NK, Suh CO, Keum KC, Kim YB, Ahn SD, Kim SS, Ha SW, Chie EK, Kim K, Shin HS, Kim JH, et al. The role of postmastectomy radiation therapy after neoadjuvant chemotherapy in clinical stage II-III breast cancer patients with pN0: a multicenter, retrospective study (KROG 12-05). Int J Radiat Oncol Biol Phys. 2014; 88:65-72.
11. McGuire SE, Gonzalez-Angulo AM, Huang EH, Tucker SL, Kau SW, Yu TK, Strom EA, Oh JL, Woodward WA, Tereffe W, Hunt KK, Kuerer HM, Sahin AA, et al. Postmastectomy radiation improves the outcome of patients with locally advanced breast cancer who achieve a pathologic complete response to neoadjuvant chemotherapy. Int J Radiat Oncol Biol Phys. 2007; 68:1004-1009.
12. Beriwal S, Shinde A, Rajagopalan MS, Kannan N, Heron DE and Deutsch M. Recommendations for post-mastectomy radiation therapy after neo-adjuvant chemotherapy: an International Survey of Radiation Oncologists. Breast J. 2013; 19:683-684.
13. Fritz A PC, Jack A, Shanmugaratnam K, Sobin L, Parkin DM, Whelan S. (2000). International Classification of Diseases for Oncology (ICD-O) 3. Geneva: World Health Organization;.
14. Klebanoff MA and Cole SR. Use of multiple imputation in the epidemiologic literature. Am J Epidemiol. 2008; 168:355-357.
15. Janssen KJ, Donders AR, Harrell FE, Jr., Vergouwe Y, Chen Q, Grobbee DE and Moons KG. Missing covariate data in medical research: to impute is better than to ignore. J Clin Epidemiol. 2010; 63:721-727.
16. Liao SG, Lin Y, Kang DD, Chandra D, Bon J, Kaminski N, Sciurba FC and Tseng GC. Missing value imputation in high-dimensional phenomic data: imputable or not, and how? BMC Bioinformatics. 2014; 15:346.
17. Little RJ, Rubin DB. (2002). Statistical Analysis with Missing Data (Second Edition). (New York: John Wiley & Sons;).
18. Normand ST, Landrum MB, Guadagnoli E, Ayanian JZ, Ryan TJ, Cleary PD and McNeil BJ. Validating recommendations for coronary angiography following acute myocardial infarction in the elderly: a matched analysis using propensity scores. J Clin Epidemiol. 2001; 54:387-398.
19. R Core Team 2014. A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. URL http://www.R-project. org/.
20. Gralow JR, Burstein HJ, Wood W, Hortobagyi GN, Gianni L, von Minckwitz G, Buzdar AU, Smith IE, Symmans WF, Singh B and Winer EP. Preoperative therapy in invasive breast cancer: pathologic assessment and systemic therapy issues in operable disease. J Clin Oncol. 2008; 26:814-819.
21. Mamounas TP. Predicting locoregional recurrence after neoadjuvant chemotherapy in patients with breast cancer. Clin Adv Hematol Oncol. 2013; 11:175-177.
22. Hardenbergh PH, Bentel GC, Prosnitz LR and Marks LB. Postmastectomy radiotherapy: toxicities and techniques to reduce them. Semin Radiat Oncol. 1999; 9:259-268.
23. Mamounas EP, Anderson SJ, Dignam JJ, Bear HD, Julian TB, Geyer CE, Jr., Taghian A, Wickerham DL and Wolmark N. Predictors of locoregional recurrence after neoadjuvant chemotherapy: results from combined analysis of National Surgical Adjuvant Breast and Bowel Project B-18 and B-27. J Clin Oncol. 2012; 30:3960-3966.
24. Huang EH, Tucker SL, Strom EA, McNeese MD, Kuerer HM, Hortobagyi GN, Buzdar AU, Valero V, Perkins GH, Schechter NR, Hunt KK, Sahin AA and Buchholz TA. Predictors of locoregional recurrence in patients with locally advanced breast cancer treated with neoadjuvant chemotherapy, mastectomy, and radiotherapy. Int J Radiat Oncol Biol Phys. 2005; 62:351-357.